spironolactone has been researched along with Hypertension, Pulmonary in 21 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the efficacy of MR antagonism by spironolactone in two experimental PH models; mouse chronic hypoxia-induced PH (prevention model) and rat monocrotaline-induced PH (prevention and treatment models)." | 3.79 | Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. ( Fanburg, BL; Hill, NS; Jaffe, IZ; Preston, IR; Sagliani, KD; Warburton, RR, 2013) |
| "A rare case of childhood pulmonary haemosiderosis with juvenile idiopathic arthritis is discussed, with particular reference to treatment with hydroxychloroquine and sildenafil for pulmonary hypertension which occurs secondary to this disease." | 3.74 | Pulmonary haemosiderosis with juvenile idiopathic arthritis in a Malaysian child. ( Noor, AS; Quah, BS; Rasool, AH; Roberton, D; Wong, AR, 2007) |
| "Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension." | 1.34 | [Portopulmonary hypertension due to schistosomiasis in two Malagasy patients]. ( Rajaona, HR; Rajaonarivelo, P; Ramanampamonjy, RM; Razafimahefa, SH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Grimmer, B | 1 |
| Krauszman, A | 1 |
| Hu, X | 1 |
| Kabir, G | 1 |
| Connelly, KA | 1 |
| Li, M | 1 |
| Grune, J | 1 |
| Madry, C | 1 |
| Isakson, BE | 1 |
| Kuebler, WM | 1 |
| Elinoff, JM | 2 |
| Chen, LY | 1 |
| Dougherty, EJ | 1 |
| Awad, KS | 1 |
| Wang, S | 1 |
| Biancotto, A | 1 |
| Siddiqui, AH | 1 |
| Weir, NA | 1 |
| Cai, R | 1 |
| Sun, J | 2 |
| Preston, IR | 2 |
| Solomon, MA | 2 |
| Danner, RL | 2 |
| Sagliani, KD | 1 |
| Warburton, RR | 1 |
| Hill, NS | 1 |
| Fanburg, BL | 1 |
| Jaffe, IZ | 1 |
| Rame, JE | 1 |
| Forfia, PR | 1 |
| Hall, MK | 1 |
| Gharib, AM | 1 |
| Abd-Elmoniem, K | 1 |
| Graninger, G | 1 |
| Harper, B | 1 |
| Maron, BA | 2 |
| Waxman, AB | 1 |
| Opotowsky, AR | 1 |
| Gillies, H | 1 |
| Blair, C | 1 |
| Aghamohammadzadeh, R | 1 |
| Loscalzo, J | 2 |
| Leopold, JA | 2 |
| Shah, AM | 1 |
| Shah, SJ | 1 |
| Anand, IS | 1 |
| Sweitzer, NK | 1 |
| O'Meara, E | 1 |
| Heitner, JF | 1 |
| Sopko, G | 1 |
| Li, G | 1 |
| Assmann, SF | 1 |
| McKinlay, SM | 1 |
| Pitt, B | 1 |
| Pfeffer, MA | 1 |
| Solomon, SD | 1 |
| Wong, AR | 1 |
| Noor, AS | 1 |
| Rasool, AH | 1 |
| Quah, BS | 1 |
| Roberton, D | 1 |
| Bansal, S | 1 |
| Badesch, D | 1 |
| Bull, T | 1 |
| Schrier, RW | 1 |
| Chabot, A | 1 |
| Jiang, BH | 1 |
| Shi, Y | 1 |
| Tardif, JC | 1 |
| Dupuis, J | 1 |
| Zhang, YY | 1 |
| White, K | 1 |
| Chan, SY | 1 |
| Handy, DE | 1 |
| Mahoney, CE | 1 |
| Carrascosa, MF | 1 |
| Larroque, IC | 1 |
| Rivero, JL | 1 |
| García, JA | 1 |
| Hoz, MC | 1 |
| Ares, MA | 1 |
| López, XA | 1 |
| Caviedes, JR | 1 |
| HAENEL, J | 1 |
| Murcia Sánchez, E | 1 |
| Germán, MJ | 1 |
| Ibáñez, V | 1 |
| Pérez-Cerdá, F | 1 |
| Alam, S | 1 |
| Palevsky, HI | 1 |
| Ramanampamonjy, RM | 1 |
| Razafimahefa, SH | 1 |
| Rajaonarivelo, P | 1 |
| Rajaona, HR | 1 |
| Giannarelli, C | 1 |
| De Giorgi, A | 1 |
| De Negri, F | 1 |
| Carmassi, F | 1 |
| Braun, I | 1 |
| Schröder, R | 1 |
| Ramdohr, B | 1 |
| Hüttemann, U | 1 |
| von Leitner, E | 1 |
| Schüren, KP | 1 |
| Malmquist, J | 1 |
| Trell, E | 1 |
| Torp, A | 1 |
| Lindström, C | 1 |
| Kühn, P | 1 |
| Probst, P | 1 |
| Botticelli, JT | 1 |
| Schlueter, DP | 1 |
| Lange, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension[NCT01712620] | Phase 2 | 70 participants (Anticipated) | Interventional | 2014-01-10 | Recruiting | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
1 review available for spironolactone and Hypertension, Pulmonary
| Article | Year |
|---|---|
Standard therapies for pulmonary arterial hypertension.
Topics: Anticoagulants; Calcium Channel Blockers; Comorbidity; Diuretics; Heart Failure; Humans; Hypertensio | 2007 |
5 trials available for spironolactone and Hypertension, Pulmonary
15 other studies available for spironolactone and Hypertension, Pulmonary
| Article | Year |
|---|---|
Pannexin 1: a novel regulator of acute hypoxic pulmonary vasoconstriction.
Topics: Adenosine Triphosphate; Animals; Calcium; Connexins; HeLa Cells; Humans; Hypertension, Pulmonary; Hy | 2022 |
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Endo | 2018 |
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
Topics: Aldosterone; Animals; Arterial Pressure; Body Weight; Cardiac Output; Cell Proliferation; Fibrosis; | 2013 |
Pulmonary haemosiderosis with juvenile idiopathic arthritis in a Malaysian child.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Juvenile; Female; Hemosideros | 2007 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
Topics: Aldosterone; Animals; Cells, Cultured; Cysteine; Disease Models, Animal; Endothelial Cells; Endothel | 2012 |
Pulmonary arterial hypertension associated with neurofibromatosis type 1.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Diuretics; Dyspnea; Fatal Outcome; Female; Follow-U | 2010 |
[THE EFFECT OF ALDACTONE ON ADVANCED RESPIRATORY INSUFFICIENCY (RESPIRATORY ACIDOSIS) IN CHRONIC COR PULMONALE].
Topics: Acidosis, Respiratory; Bicarbonates; Blood Gas Analysis; Body Fluids; Carbon Dioxide; Humans; Hydrog | 1963 |
[Anesthetic management for mediastinoscopy in a patient with severe pulmonary hypertension].
Topics: Anesthesia, General; Bundle-Branch Block; Dermatomyositis; Dyslipidemias; Epoprostenol; Female; Fent | 2007 |
[Portopulmonary hypertension due to schistosomiasis in two Malagasy patients].
Topics: Adolescent; Adult; Anthelmintics; Ascites; Combined Modality Therapy; Diet, Sodium-Restricted; Dyspn | 2007 |
Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diet, Sodium-Restricted; Di | 2007 |
[Aldactone therapy in ambulatory patients with exertion-induced cardiorespiratory insufficiency. Preliminary report].
Topics: Adult; Aged; Ambulatory Care; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, | 1976 |
A case of drug-induced (?) pulmonary hypertension.
Topics: Appetite Depressants; Dextroamphetamine; Female; Furosemide; Humans; Hypertension, Pulmonary; Middle | 1970 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |
Pulmonary venous and arterial hypertension due to chronic fibrous mediastinitis. Hemodynamics and pulmonary function.
Topics: Adult; Chlorothiazide; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Med | 1966 |